Last reviewed · How we verify
Rupax (RUPATADINE)
At a glance
| Generic name | RUPATADINE |
|---|---|
| Sponsor | Teikoku Seiyaku |
| Drug class | rupatadine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2001 |
Approved indications
- Allergic rhinitis
- Urticaria
Common side effects
Key clinical trials
- Rupatadine in Patients With Ulcerative Colitis (PHASE2)
- Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants. (PHASE1)
- Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants (PHASE1)
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions (PHASE1)
- Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria (PHASE2)
- Chronic Urticaria - Long Term Assessment of Effects of Rupatadine (PHASE3)
- Effect of Some Drugs on Rheumatoid Arithritis Activity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rupax CI brief — competitive landscape report
- Rupax updates RSS · CI watch RSS
- Teikoku Seiyaku portfolio CI